Life Science News

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that it will soon be available for order online throughout the United States through GTFO It's Vegan, a progressive online vegan market serving consumers across the U.S

Komo received a purchase order from GTFO and plans to ship its first pallet of Komo plant-based comfort foods to GTFO headquarters in California this week. Consumers across the United States will soon be able to order, for home delivery, all of Komo's frozen products online at GTFO It's Vegan.

"We are very excited and grateful to be the first to launch Komo Comfort Foods into the U.S. market. We are confident Komo's innovative line of great tasting heat and serve meals, including Lasagna, Chickenless Pot Pie and Shepherd's Pie, will quickly become fan favorites for GTFO It's Vegan customers," says Marc Pierce, Co-Founder and CEO, GTFO - It's Vegan.

Recognizing the rapid growth of the plant-based market, GTFO It's Vegan launched in 2020 to appeal to the needs of all individuals seeking a more healthy lifestyle. This extends well beyond vegans and includes vegetarians, flexitarians, athletes, and those with diet allergies and sensitivities. GTFO It's Vegan tries all the products it sells to ensure they meet GTFO's taste, texture, scent, appearance, and packaging standards to sell to its community of tens of thousands customers enthusiastic about vegan and plant-based foods.

Komo first launched its product for direct-to-consumer sales in Vancouver, British Columbia, Canada in March 2021 through its eCommerce platform and has received over 200 five star (out of five) reviews from its online consumers, as seen on its website at www.komocomfortfoods.com.

"We are so excited to soon have Komo Comfort Foods available to consumers across the United States through GTFO It's Vegan," says Komo CEO William White. "At Komo we believe plant-based eating is the future and change can start with a single bite. Being on the GTFO eCommerce platform will further our mission to help make plant-based meals a staple on every dinner table."

About GTFO

Launched May 15, 2020, GTFO It's Vegan has quickly emerged as a leading player in the online vegan grocery market, delivering vegan food across the United States. GTFO strives to be the destination for everything vegan, for everybody, everywhere, to help ensure the sustainability of people and the planet. To learn more about GTFO It's Vegan, visit www.gtfoitsvegan.com or email support@gtfoitsvegan.com.

About Komo

Komo Plant Based Foods Inc. is a premium plant-based food company that develops, manufactures and sells a variety of plant-based frozen meals that are always hearty, satisfying, and made with wholesome ingredients. At Komo, our mission is to help make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. We believe plant-based eating is the future and - Change can start with a single biteTM. Our experienced plant-based innovation and development team recreates vegan versions of traditionally cheesy and meaty classics, with 100% plants. Komo's products are sold direct-to-consumer through our eCommerce website and a distribution network of online and brick and mortar grocery, convenience and natural retailer channels. Our operating subsidiary Komo Comfort Foods launched in 2021 with our flagship products: plant-based Lasagna, Shepherd's Pie and Chickenless Pot Pie and has recently launched a new line - Komo Plant-Based Meal HelpersTM - versatile meal starters to allow the creation of many dishes at home. All of our products are 100% plant-based, made with wholesome ingredients, free from preservatives, and frozen for freshness. Freezing products is a natural and effective way of keeping food products for longer without having to use any preservatives. Komo's meals have a 1-year frozen shelf life. Komo also sells hot ready-to-eat meals in Metro Vancouver through Uber Eats and Skip the Dishes.

Learn more at: www.komocomfortfoods.com and follow on Instagram: @komocomfortfoods

For further information, please contact:

William White, President & CEO, Komo Plant Based Foods Inc.
will@komoeats.com
1-866-969-0882

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or Komo's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Komo's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, Komo's product development plans, its ability to launch its products on food delivery apps, its ability to retain key personnel, its revenues, and its expectation as to the acceptance of its products by retailer stores and consumers constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Komo disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

SOURCE:Komo Plant Based Foods Inc.



View source version on accesswire.com:
https://www.accesswire.com/685319/Komo-Plant-Based-Foods-to-be-Available-for-Online-Purchase-Across-the-United-States-through-GTFO-Its-Vegan

News Provided by ACCESSWIRE via QuoteMedia

YUM:CC
Komo Plant-Based Foods

Komo Plant-Based Foods


Keep reading...Show less
Komo Plant Based Foods Inc. Establishes US Cold Storage Partnership

Komo Plant Based Foods Inc. Establishes US Cold Storage Partnership

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce it will be partnering with HLC Distributing as a third-party logistics (3PL) Warehouse for the U.S

"We are thrilled to work with Komo foods as they look to expand into the US market. They're an innovative company that understands the plant-based segment," said Alec Hendren, Vice President of HLC Distributing (HLC). "As a cold storage and logistics provider, we are excited to help provide the resources needed to get great products out into the market. It's the right fit for both companies and I look forward to building the relationship as we both grow."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Grows Distribution Across Quebec, Ontario, and Maritimes

Komo Plant Based Foods Grows Distribution Across Quebec, Ontario, and Maritimes

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB:KOMOF) (FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that Horizon Nature is now carrying all Komo frozen plant-based products for distribution, with a focus on Quebec and the Maritimes with a growing market in Ontario

Horizon Nature is a full service distributor to natural, independent and grocery banners. Founded in 2003, the company is still a Quebec family owned business today. Operating from a vast and modern distribution centre in St-Léonard, Horizon Nature offers a wide variety of local, national and global brands supported by an experienced sales team. As a supplier to Metro, Provigo, Tau and Avril, they offer a range of products spanning from fresh to dry grocery and frozen, with an emphasis on healthy whole foods as well as products across various dietary needs, whether gluten free or vegan ingredients and meals.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Shares Canadian Retail Update

Komo Plant Based Foods Shares Canadian Retail Update

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB:KOMOF) (FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce it's now being carried in a total of 240 distribution points across Canada; 39 of which are in Eastern Canada

According to a 2020 Statista Report there are 2.3 million vegetarians in Canada and an additional 850,000 classified themselves as vegan. Research conducted by the Angus Reid Institute (Canadian non-profit independent research organization) has found that 1 in 5 Canadians (22%) who regularly eat meat would like to reduce the amount of meat they consume. In eastern Canada, which has a population of 14 million, people spend an average of $10,418 per year on food. Source: https://www.statista.com/statistics/567888/average-annual-household-expenditures-in-ontario-canada/

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Launches in Whole Foods Market Retail Locations in Western Canada

Komo Plant Based Foods Launches in Whole Foods Market Retail Locations in Western Canada

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB: KOMOF) (FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce it's now being carried in 4 out of 7 western Whole Foods Market locations

Whole Foods Market, Inc. is an American multinational supermarketchain headquartered in Austin, Texas, which sells organic foods and products free from hydrogenated fats and artificial colors, flavors, and preservatives. Whole Foods seeks out the finest natural and organic foods available, maintains the strictest quality standards in the industry, and has an unshakeable commitment to sustainable agriculture. Whole Foods has more than 500 retail and non-retail locations in the US, Canada and the United Kingdom. It has 14 retail locations in Canada, of which 7 are in British Columbia, and 7 are in Ontario. In 2017, Amazon purchased Whole Foods Market for USD$13.7 Billion.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Komo Plant-Based Foods Awarded Best New Vegan Product of Expo West 2022

Komo Plant-Based Foods Awarded Best New Vegan Product of Expo West 2022

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo" or the "Company") a premium plant-based food company, made its first in-person, U.S. trade show debut at Natural Products Expo West (NPEW), at the Anaheim Convention Center in Anaheim, California. At the conference, Komo took home the VegNews Best of Show Award 2022 for Best New Vegan Product of the show

Founded in 2000, VegNews is one of the most established vegan news sources in the world. It produces four magazines annually, reaching 3.6 million people monthly across print, digital, and social media.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
The Gummy Project

Potent Ventures Announces The Gummy Project Selected by Sweets & Snack Expo Committee to Participate in Power Pitch During Sweets & Snacks Expo

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is pleased to announce that The Gummy Project is one of two companies selected from the show's Startup Street to participate in Power Pitch at Sweets & Snacks Expo on May 24, 2022.

Power Pitch provides selected companies with an opportunity to showcase their products in a sales pitch-style presentation to a panel of leading US retailers, including the following:

Keep reading...Show less

Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

Late-Breaking TROPiCS-02 Study Results in Heavily Pre-Treated HR+HER2- Metastatic Breast Cancer Patients to be Featured in ASCO Press Program –

New Sub-Analysis from Kite's ZUMA-7 CAR T-cell Therapy Study in Patients Aged 65+ and Data by Tumor Burden Characteristics in Second-Line Large B-cell Lymphoma to be Presented

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. (ABBVie) (NYSE:ABBV) on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive (the "Class Period

CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/abbvie-inc?utm_source=PR&utm_medium=link&utm_campaign=abbvie&mktm=r

CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE

TO VIEW OUR COMPLAINT, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE: JUNE 6, 2022

CLASS PERIOD: APRIL 30, 2021 through AUGUST 31, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS: James Maro, Esq. (484) 270-1453 or Email at info@ktmc.com

Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

ABBVIE'S ALLEGED MISCONDUCT

AbbVie is one of the world's largest pharmaceutical companies. The company's revenues will come under significant pressure in the coming years when its best-selling drug, Humira, will lose patent protection in 2023. Accordingly, AbbVie's future revenue and earnings depend in large part on its ability to develop new sources of revenue to offset Humira's lost sales. Rinvoq-an anti-inflammatory drug manufactured by AbbVie and used to treat rheumatoid arthritis (RA) and other diseases by inhibiting Janus kinase (JAK) enzymes-was touted as one such drug. Rinvoq was initially approved in the United States to treat only moderate to severe RA. However, AbbVie was actively pursuing additional treatment indications and, in 2020, asked the U.S. Food and Drug Administration (FDA) to approve Rinvoq for the treatment of several other diseases.

As is relevant here, Rinvoq is similar to other JAK inhibitor drugs, including Xeljanz, manufactured by Pfizer Inc. When the FDA approved Xeljanz in 2012 for the treatment of RA, it required an additional safety trial to evaluate Xeljanz's risk of triggering certain serious side effects. Beginning in February 2019, the FDA repeatedly warned the public that the safety trial indicated that Xeljanz's use could lead to serious heart-related issue, cancer, and other adverse events. Notwithstanding the similarities between Rinvoq and Xeljanz, during the Class Period, Defendants assured investors that Rinvoq was far safer than Xeljanz and not subject to the same regulatory risks.

However, investors began to learn the truth about Rinvoq's significant risks on June 25, 2021, when AbbVie revealed that the FDA was delaying its review of expanded treatment applications for Rinvoq due to the safety concerns associated with Xeljanz. On this news, the price of AbbVie common stock declined $1.76 per share, or approximately 1.5%, from a close of $114.74 per share on June 24, 2021, to close at $112.98 per share on June 25, 2021.

Then, on September 1, 2021, the FDA announced that final results from the Xeljanz safety trial established an increased risk of serious adverse events, even with low doses of Xeljanz. As a result, the FDA determined that it would require new and updated warnings for Xeljanz and Rinvoq because Rinvoq "share[s] similar mechanisms of action with Xeljanz" and "may have similar risks as seen in the Xeljanz safety trial." The FDA also indicated that it would further limit approved indications for Rinvoq as a result of these safety concerns. On this news, the price of AbbVie common stock declined $8.51 per share, or more than 7%, from a close of $120.78 per share on August 31, 2021, to close at $112.27 per share on September 1, 2021.

After the Class Period, on December 3, 2021, AbbVie announced that the FDA had updated Rinvoq's label to require additional safety warnings and limit marketing of Rinvoq to only its use after treatment with other drugs has failed. On January 11, 2022, Defendants admitted that these changes to Rinvoq's label would negatively impact sales, forcing the Company to reduce its long-term guidance for Rinvoq's sales in 2025.

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company's business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

WHAT CAN I DO?

AbbVieinvestors may, no later than June 6, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLPor other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages AbbVie investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP



View source version on accesswire.com:
https://www.accesswire.com/701263/Investor-Reminder-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Investors-of-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-Filed-Against-AbbVie-Inc

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

IBM, ABBV, & TWTR Class Actions: Bronstein, Gewirtz & Grossman, LLC, A Leading Class Action Firm Reminds Investors to Actively Participate

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Bronstein, Gewirtz and Grossman, LLC, Tuesday, May 17, 2022, Press release picture

International Business Machines Corporation (NYSE:IBM)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

CLASS ACTION UPDATE for ABBV, LILM and NTRA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you

ABBV Shareholders Click Here: https://www.zlk.com/pslra-1/abbvie-inc-loss-submission-form?prid=27357&wire=1
LILM Shareholders Click Here: https://www.zlk.com/pslra-1/lilium-n-v-f-k-a-qell-acquisition-corp-loss-submission-form?prid=27357&wire=1
NTRA Shareholders Click Here: https://www.zlk.com/pslra-1/natera-inc-loss-submission-form?prid=27357&wire=1

* ADDITIONAL INFORMATION BELOW *

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces FDA Investigational New Drug Application  Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx for Recurrent Pericarditis

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx for Recurrent Pericarditis

  • Third IND authorization for CardiolRx™ in cardiovascular disease
  • Study to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently
  • CardiolRx™ is now eligible for orphan drug status in two indications

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug Application (IND) to commence a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx™, a pharmaceutically manufactured oral cannabidiol drug formulation, in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™. Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx™ eligible for orphan drug status under the FDA's Orphan Drug Designation program.

Allan L. Klein, MD, FRCP (C), FACC, FAHA, FASE, FESC, Director Center of Pericardial Diseases and Professor of Medicine, Heart and Vascular Institute, Cleveland Clinic, will serve as study Chair and provide leadership throughout the course of the trial. Dr. Klein commented, "I look forward to investigating the potential of this treatment in patients with recurrent pericarditis, a cardiovascular inflammatory disease and the most common of pericardial diseases. We look forward to evaluating whether this intervention could be a therapeutic option for those who are intolerant to current medical treatment or who require long-term administration of corticosteroids to control their disease."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×